A Dermatologist Is Begging People To Wash This 'Often Neglected' Body Part
For some people, showering and bathing isn't just a way to get clean; it's a form of self-care (you've heard of the "everything shower," right?). Their shelves are stocked with a variety of luscious-smelling products, and they'll splurge for the expensive shampoo. Other people are quick with their rinses, seeing washing off as a basic necessity or chore; they're in and out.We're all different, and we all have different approaches to getting clean. Regardless of what type of bath or shower you choose or when you prefer to rinse off—there's a bit of a divide between those of us who like to shower in the mornings, and those who prefer the nighttime—there's a good chance that you're forgetting to wash one specific body part, and it can lead to some pretty gross health problems.
🩺SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week💊
A Dermatologist Is Begging People To Wash This 'Often Neglected' Body Part
When was the last time you made a conscious effort to wash your belly button? If you can't remember, that's a problem. 'Belly buttons, even outies but especially innies, are the perfect breeding ground for bacteria. It's dark, damp and often neglected when cleaning,' says Dr. Geeta Yadav, MD, a board-certified dermatologist and founder of FACET Dermatology. Dr. Yadav explains that sweat, dead skin cells, sebum, dirt and debris (like fuzz from clothing) build up in the belly button, giving bacteria plenty of food to thrive. She says that not only can this cause the belly button to develop a foul odor, but it can also cause infections.
Related:
One scientific study found 67 different types of bacteria on the belly buttons of the study participants. Where does it all come from? 'Bacteria is everywhere!' Dr. Yadav says. 'There are 'good' and 'bad' bacteria on our skin at all times, and other factors—like swimming in the ocean, working out at a gym, rewearing dirty clothes or sleeping in used sheets—can introduce new bacteria.'Another scientific study found that the more bacteria a belly button has, the stronger the odor is. PSA: A clean belly button doesn't have a smell. In the most extreme cases of neglect, Dr. Yadav says that umboliths (also spelled 'omphaloliths'), or naval stones, can develop. 'Umboliths are masses made up of sebum, dead skin, hair and other debris that become hard and compacted, similar to an old blackhead. They are not common, but are most likely to form in individuals with very deep 'innie' belly buttons,' she explains.Related:
The Best Way To Keep Your Belly Button Clean
Who knew the humble belly button could get so disgusting, right? Knowing what can happen, chances are you're going to be paying it proper attention from now on. 'Every time you bathe, you should be thoroughly cleaning your belly button with body wash,' Dr. Yadav says.
She says that, typically, using your finger to clean it is adequate (as long as your finger fits in there), explaining, 'Just swirl your finger around inside with body wash, then rinse thoroughly. If you want to be more thorough, you can use a washcloth."
Related:
In terms of what type of cleaning products are best for washing your belly button, Dr. Yadav shares that body wash and your finger are typically all the cleaning tools you need. 'You can also use a liquid chemical exfoliant on a cotton swab if you're concerned about odor and buildup,' she adds. But if you have good hygiene habits, she says that washing your belly button when you wash the rest of your body is enough.
With all this in mind, you should be washing your belly button every time you bathe or shower. That way, you can rest assured there won't be any weird smells coming from it or anything sinister hiding out there that shouldn't be there.
It only takes a few seconds to properly clean the belly button, but it's a crucial few seconds. Give your belly button some undivided attention. That way, it stays healthy and clean.
Up Next: Sources:
Dr. Geeta Yadav, MD, board-certified dermatologist and founder of FACET Dermatology
A Jungle In There: Bacteria in Belly Buttons Is Highly Diverse, but Predictable.PLoS One. 2012
Microbiota in Umbilical Dirt and Its Relationship with Odor. Microbes and Environments. 2023
Omphalolith: An underdiagnosed entity. Clinical Case Reports. 2022
A Dermatologist Is Begging People To Wash This 'Often Neglected' Body Part first appeared on Parade on Jul 20, 2025
This story was originally reported by Parade on Jul 20, 2025, where it first appeared.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths SAN ANTONIO, July 22, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. "As with the recent announcement of the award of our patent in China, this Canadian patent reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives," said Maria Zannes, President and CEO of bioAffinity Technologies. Lung cancer is the leading cause of cancer death in Canada, according to the Canadian Cancer Society. In 2024, approximately 31,000 Canadians were diagnosed with lung cancer, and approximately 20,700 people died of the disease. More than 70% of the lung cancer deaths were linked to smoking. "We believe that the award of this patent by the Canadian Patent Office further validates the diagnostic platform behind CyPath® Lung, expands the global footprint of our intellectual property portfolio and highlights the strength of our science," Ms. Zannes said. "Recent case studies highlight CyPath Lung's ability to detect lung cancer at its earliest stages, making our test all the more valuable in Canada where 50% of all lung cancer cases are diagnosed late at Stage IV with the five-year survival rate overall of about 19% in Canada, according to government statistics." The Canadian patent (Patent No. 3,136,245) – titled "System and Method for Determining Lung Health" – protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum. CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. About CyPath® Lung CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath® Lung in Canada. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath® Lung in Canada, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. View source version on Contacts bioAffinity Technologies Julie Anne OvertonDirector of Communicationsjao@ Investor Relations Dave GentryRedChip Companies Inc.1-800-RED-CHIP (733-2447) or 407-491-4498BIAF@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Top Analyst Calls UnitedHealth a 'Top Pick' Ahead of Earnings
July 22 - UnitedHealth Group (NYSE:UNH) has tumbled roughly 42% year?to?date, driven by rising Medicare Advantage costs, a surprise CEO exit, withdrawn guidance and a Department of Justice probe. However, ahead of its July 29 Q2 earnings, Bernstein analyst Lance Wilkes tapped UNH as a 'Top Pick,' saying the pullback creates an attractive entry point. He noted the stock trades at about 13.5 times forward earnings, below its ten?year average. Warning! GuruFocus has detected 4 Warning Sign with UNH. Wilkes cut his 2025 EPS estimate by 10% to reflect reserve strengthening and cost pressures in individual and Medicaid segments, plus a cleanup of OptumHealth risk contracts. Yet he projects earnings per share could double by 2029, implying a 19% compound annual growth rate. The analyst expects cost normalization to begin in Medicaid in Q3 and in Medicare Advantage in early 2026 as utilization patterns stabilize. He also highlighted a hardening pricing environment for government managed?care plans as a margin tailwind. Is UNH Stock a Buy? Based on the one year price targets offered by 24 analysts, the average target price for UnitedHealth Group Inc is $375.46 with a high estimate of $677.00 and a low estimate of $270.00. The average target implies a upside of +33.08% from the current price of $282.14. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Sleep Number Corporation to Announce Second Quarter 2025 Results on July 30, 2025
MINNEAPOLIS, July 22, 2025--(BUSINESS WIRE)--Sleep Number Corporation (Nasdaq: SNBR) will release its fiscal second quarter results through June 28, 2025, before market open on Wednesday, July 30, 2025. Management will host its regularly scheduled conference call to discuss the company's results at 8:30 a.m. EDT (7:30 a.m. CDT; 5:30 a.m. PDT). To access the webcast, please visit the investor relations area of the Sleep Number website at The webcast replay will remain available for approximately 60 days. About Sleep Number Corporation Sleep Number is a sleep wellness company. We are guided by our purpose to improve the health and wellbeing of society through higher quality sleep. To date, our innovations have improved nearly 16 million lives. Our sleep wellness platform helps solve sleep problems, whether it's providing individualized temperature control for each sleeper through our Climate360 smart bed or applying our 34 billion hours of longitudinal sleep data and expertise to research with global institutions. Our smart bed ecosystem helps people sleep better by offering adjustable comfort and personalized sleep and health insights. Millions of Smart Sleepers benefit from higher quality sleep, and our 3,400 dedicated team members are passionate about creating innovative solutions through our vertically integrated business model, including direct-to-consumer selling in 630 stores and online. To learn more about life-changing, individualized sleep, visit a Sleep Number® store near you, our newsroom and investor relations sites, or View source version on Contacts Investor Contact investorrelations@ Media Contact Muriel Lussier, Sleep Number Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data